This company listing is no longer active
eFFECTOR Therapeutics Management
Management criteria checks 1/4
eFFECTOR Therapeutics' CEO is Steve Worland, appointed in May 2012, has a tenure of 11.83 years. total yearly compensation is $3.84M, comprised of 14.7% salary and 85.3% bonuses, including company stock and options. directly owns 0.73% of the company’s shares, worth €420.88K. The average tenure of the management team and the board of directors is 3.3 years and 2.6 years respectively.
Key information
Steve Worland
Chief executive officer
US$3.8m
Total compensation
| CEO salary percentage | 14.7% |
| CEO tenure | 11.8yrs |
| CEO ownership | 0.7% |
| Management average tenure | 3.3yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$36m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$37m |
| Mar 31 2023 | n/a | n/a | -US$36m |
| Dec 31 2022 | US$4m | US$567k | -US$23m |
| Sep 30 2022 | n/a | n/a | US$6m |
| Jun 30 2022 | n/a | n/a | US$24m |
| Mar 31 2022 | n/a | n/a | US$25m |
| Dec 31 2021 | US$3m | US$501k | US$16m |
| Sep 30 2021 | n/a | n/a | -US$4m |
| Jun 30 2021 | n/a | n/a | -US$20m |
| Mar 31 2021 | n/a | n/a | -US$7m |
| Dec 31 2020 | US$645k | US$452k | US$166k |
Compensation vs Market: Steve's total compensation ($USD3.84M) is above average for companies of similar size in the German market ($USD390.92K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
CEO
Steve Worland (65 yo)
11.8yrs
Tenure
US$3,843,052
Compensation
Dr. Stephen T. Worland, also known as Steve, Ph.D. serves as Director at Blacksmith Medicines, Inc. He has been President and Chief Executive Officer of eFFECTOR Therapeutics, Inc. since May 2012 and has b...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 11.8yrs | US$3.84m | 0.73% € 420.9k | |
| Chief Financial Officer | 3.3yrs | US$1.98m | 0.038% € 22.0k | |
| Chief Medical Officer | 1.6yrs | US$711.96k | 0% € 0 | |
| Co-Founder and Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Co-Founder and Member of Clinical & Scientific Advisory Board | no data | no data | no data |
3.3yrs
Average Tenure
51yo
Average Age
Experienced Management: LWK1's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.6yrs | US$3.84m | 0.73% € 420.9k | |
| Co-Founder and Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Co-Founder and Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.6yrs | US$80.86k | 0.032% € 18.4k | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | 0.0079% € 4.6k | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 4.2yrs | US$104.86k | 0.026% € 15.2k | |
| Independent Director | 3.2yrs | US$74.58k | 0% € 0 | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data |
2.6yrs
Average Tenure
57.5yo
Average Age
Experienced Board: LWK1's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/26 02:44 |
| End of Day Share Price | 2023/12/28 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
eFFECTOR Therapeutics, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Judah Frommer | Credit Suisse |
| Robert Burns | H.C. Wainwright & Co. |